AstraZeneca stock
AZNNYSEAstraZeneca PLC, HealthcareISIN GB0009895292
73Score 73 out of 100, Strong
Price and trend
65 / 100
Price history
+5.0% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 2.3% above it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 12% below its 52-week high. Largest decline in 20 years: 49% (February 2007 to March 2009).
Chart figures for advanced users
- SMA 50$168.41
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$180.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$155.62
- The lowest closing price of the last twelve months.
- Resistance$209.48
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AstraZeneca PLC belongs to the Drug Manufacturers (General) industry (United Kingdom) and, with a market value of $285.95B, is number 7 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $58.74B (up 8.6% year on year) and earnings of $10.26B (up 45.8%).
- For fiscal 2026, analysts expect on average revenue of $62.71B (up 6.8%) and adjusted earnings per share of $10.26 (up 12%).
Show more
- MEQIRI Score 73 out of 100 (Strong): rank 95 of 702 in Healthcare, median 53.
- The P/E is 26.2 (Drug Manufacturers (General) median 25.7, own median of recent years 35.3).
- Our model puts fair value at $201.17, with the price 8% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 22% a year since 2020.Growth 92
- Growing faster than its industryRevenue up 17.2% a year since 2020, Drug Manufacturers (General) median 6.2%.Growth 92
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 87
Weaknesses
- DilutionShare count up 18% since 2020.Capital allocation 48
Its standout strengths are growth and fundamentals, while capital allocation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among the 100 largest stocks.
From 2016 to 2025, 7 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
- very large company
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $154.75 and expensive above $287.39 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $221.17 (cash-flow model) and $181.17 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $181.49, at 7.8% it would be $230.80.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 7% on the twelve months before. Revenue has grown solidly since 2006, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating 23%, net 17%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 9 Feb 2027in 88 days
- Last reported
- 30 Oct 2026EPS reported $2.79 (expected $2.60)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $10.260.0%
- Revenue
- $62.71B−0.4%
- Earnings per share
- $11.35−0.7%
- Revenue
- $66.79B−0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +1.9%2026 outlook reiterated: total revenue up by a mid to high single digit percentage and core EPS up by a low double digit percentage at constant exchange rates.
“We expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage at constant exchange rates.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $3,249 in total. One insider sold, $2.21M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AstraZeneca
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 73
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- AbbVieABBV $520.47B74
- Roche HoldingROP.SW $394.85B77
- MerckMRK $362.27B68
- NovartisNOVN.SW $304.26B75
- AmgenAMGN $252.64B76
- Gilead SciencesGILD $208.31B57
- Novo NordiskNOVO-B.CO $180.19B79
- PfizerPFE $164.33B60
ETFs that hold AstraZeneca
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree Global Quality Dividend Growth UCITS ETF USD AccWTEM | 1.46% | 0.38% | €1.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.